Alli, Xenical, Orlistat GSK (orlistat) is a small molecule pharmaceutical. Orlistat was first approved as Alli on 1998-07-29. It is used to treat obesity in the USA. It has been approved in Europe to treat obesity. The pharmaceutical is active against pancreatic triacylglycerol lipase. In addition, it is known to target diacylglycerol lipase-alpha, diacylglycerol lipase-beta, and lysophosphatidylserine lipase ABHD12.
|Trade Name||Alli, Orlistat GSK, Xenical|
|Drug Class||Enzyme inhibitors: gastrointestinal lipase inhibitors|